[Skip to Navigation]
March 1962

Experience with Measles Immunization: Alum-Absorbed Killed Measles-Virus Vaccine and Live Measles-Virus Vaccine Challenge

Author Affiliations

Samuel Karelitz, M.D., Department of Pediatrics, Long Island Jewish Hospital, New Hyde Park, N.Y.; From The Long Island Jewish Hospital, New Hyde Park, and The Eli Lilly Laboratories for Clinical Research, Indianapolis.

Am J Dis Child. 1962;103(3):427-429. doi:10.1001/archpedi.1962.02080020439055

This report deals with the evaluation of a killed alum-adsorbed measles-virus vaccine, No. CT-1199E, prepared in the laboratories of the Eli Lilly Company.

The investigation was designed to determine the effect of 1, 2, and 3 subcutaneous injections of 1 ml., given at monthly intervals, and to determine the effect on the neutralizing antibodies of a challenge injection of attenuated live measles-virus vaccine prepared at the Lederle Laboratories, Vaccine No. 7-1236-34, TCID50 of 20,000.

Neutralizing antibody determinations of the control bloods and of those obtained 1 month after the last killed-vaccine injection were made at the Lilly Laboratories. Standard control sera used contained 100 to 256 units of neutralizing antibody, and the TCID50 ranged from 50 to 416. The challenge injections were given 1 month after the killed vaccine. Neutralizing antibody titers of the bloods obtained 1 month after challenge were studied at both the Eli Lilly and

First Page Preview View Large
First page PDF preview
First page PDF preview
Add or change institution